BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 34465342)

  • 1. T cell exhaustion is associated with the risk of papillary thyroid carcinoma and can be a predictive and sensitive biomarker for diagnosis.
    Zhu C; Dai Y; Zhang H; Ruan Y; Zhou Y; Dai Y; Fan L; Jia T; Lu H; Chen Q
    Diagn Pathol; 2021 Aug; 16(1):84. PubMed ID: 34465342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-17A increases MHC class I expression and promotes T cell activation in papillary thyroid cancer patients with coexistent Hashimoto's thyroiditis.
    Han LT; Hu JQ; Ma B; Wen D; Zhang TT; Lu ZW; Wei WJ; Wang YL; Wang Y; Liao T; Ji QH
    Diagn Pathol; 2019 Jun; 14(1):52. PubMed ID: 31159823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-10 Restores MHC Class I Expression and Interferes With Immunity in Papillary Thyroid Cancer With Hashimoto Thyroiditis.
    Lu ZW; Hu JQ; Liu WL; Wen D; Wei WJ; Wang YL; Wang Y; Liao T; Ji QH
    Endocrinology; 2020 Oct; 161(10):. PubMed ID: 32348468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Papillary Thyroid Carcinoma Emerging from Hashimoto Thyroiditis Demonstrates Increased PD-L1 Expression, Which Persists with Metastasis.
    Lubin D; Baraban E; Lisby A; Jalali-Farahani S; Zhang P; Livolsi V
    Endocr Pathol; 2018 Dec; 29(4):317-323. PubMed ID: 30121940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of regulatory T cells frequency in peripheral blood and tumor tissues in papillary thyroid carcinoma with and without Hashimoto's thyroiditis.
    Liu Y; Yun X; Gao M; Yu Y; Li X
    Clin Transl Oncol; 2015 Apr; 17(4):274-80. PubMed ID: 25387566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EV PD-L1 is Correlated With Clinical Features and Contributes to T Cell Suppression in Pediatric Thyroid Cancer.
    Wang G; He L; Wang S; Zhang M; Li Y; Liu Q; Sun N; Zhang X; Liu Y; Zhang J; Tai J; Ni X
    J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32459310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epitope-Specific Antitumor Immunity Suppresses Tumor Spread in Papillary Thyroid Cancer.
    Ehlers M; Kuebart A; Hautzel H; Enczmann J; Reis AC; Haase M; Allelein S; Dringenberg T; Schmid C; Schott M
    J Clin Endocrinol Metab; 2017 Jul; 102(7):2154-2161. PubMed ID: 27860539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of cytotoxic T cells and PD-1 immune checkpoint pathway in papillary thyroid carcinoma.
    Banerjee S; Nahar U; Dahiya D; Mukherjee S; Dey P; Gupta R; Radotra B; Sachdeva N; Sood A; Bhadada SK; Bhansali A
    Front Endocrinol (Lausanne); 2022; 13():931647. PubMed ID: 36518249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of Coexistent Hashimoto's Thyroiditis on Central Compartment Lymph Node Metastasis in Papillary Thyroid Carcinoma.
    Liu Y; Lv H; Zhang S; Shi B; Sun Y
    Front Endocrinol (Lausanne); 2021; 12():772071. PubMed ID: 34867817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hashimoto's thyroiditis, nodular goiter or follicular adenoma combined with papillary thyroid carcinoma play protective role in patients.
    Ma H; Li L; Li K; Wang T; Zhang Y; Zhang C; Xu Y; Wu X; Yu J; Wang H; Xiang B; Zhang R; Wang W
    Neoplasma; 2018 Mar; 65(3):436-440. PubMed ID: 29788738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-L1 and PD-1 expression in thyroid follicular epithelial dysplasia: Hashimoto thyroiditis related atypia and potential papillary carcinoma precursor.
    Pakkanen E; Kalfert D; Ahtiainen M; Ludvíková M; Kuopio T; Kholová I
    APMIS; 2022 May; 130(5):276-283. PubMed ID: 35238073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hashimoto's thyroiditis is associated with papillary thyroid carcinoma: role of TSH and of treatment with L-thyroxine.
    Fiore E; Rago T; Latrofa F; Provenzale MA; Piaggi P; Delitala A; Scutari M; Basolo F; Di Coscio G; Grasso L; Pinchera A; Vitti P
    Endocr Relat Cancer; 2011 Aug; 18(4):429-37. PubMed ID: 21565972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Killing capacity analysis of tumor-infiltrating cytotoxic lymphocytes and impact on lymph node metastasis in differentiated papillary carcinoma of thyroid with the BRAF V600E mutation.
    Liu X; Liu H; Wang L; Han Y; Kong L; Zhang X
    Diagn Pathol; 2024 Feb; 19(1):29. PubMed ID: 38341587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Differential protein expressions in papillary thyroid carcinoma patients with or without Hashimoto's thyroiditis].
    Lu HZ; Zhang N; Liu W; Zhu XY; Qi D; Wang Y; Liu XY; Li ZJ
    Zhonghua Zhong Liu Za Zhi; 2020 Jun; 42(6):463-468. PubMed ID: 32575941
    [No Abstract]   [Full Text] [Related]  

  • 15. Diagnostic and prognostic value of tumor-infiltrating B cells in lymph node metastases of papillary thyroid carcinoma.
    Yang Z; Yin L; Zeng Y; Li Y; Chen H; Yin S; Zhang F; Yang W
    Virchows Arch; 2021 Nov; 479(5):947-959. PubMed ID: 34148127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Relationship Between IgG4-Positive Hashimoto's Thyroiditis and Papillary Thyroid Carcinoma.
    Yu Y; Zhang J; Lu G; Li T; Zhang Y; Yu N; Gao Y; Gao Y; Guo X
    J Clin Endocrinol Metab; 2016 Apr; 101(4):1516-24. PubMed ID: 26866571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of thyroglobulin epitopes in patients with autoimmune and non-autoimmune thyroid diseases using recombinant human monoclonal thyroglobulin autoantibodies.
    Latrofa F; Ricci D; Grasso L; Vitti P; Masserini L; Basolo F; Ugolini C; Mascia G; Lucacchini A; Pinchera A
    J Clin Endocrinol Metab; 2008 Feb; 93(2):591-6. PubMed ID: 18029466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Markers of immune activation: novel biomarkers to predict the early-warning indicator of patients with papillary thyroid carcinoma.
    Lu H; Zhang L; Dai Y; Ruan Y; Cao X; Cai X; Ruan S; Chen Q
    Diagn Pathol; 2020 Feb; 15(1):16. PubMed ID: 32050977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.
    Chowdhury S; Veyhl J; Jessa F; Polyakova O; Alenzi A; MacMillan C; Ralhan R; Walfish PG
    Oncotarget; 2016 May; 7(22):32318-28. PubMed ID: 27086918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence.
    Shi RL; Qu N; Luo TX; Xiang J; Liao T; Sun GH; Wang Y; Wang YL; Huang CP; Ji QH
    Thyroid; 2017 Apr; 27(4):537-545. PubMed ID: 27825291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.